362
Participants
Start Date
September 30, 2011
Primary Completion Date
October 31, 2015
Study Completion Date
October 31, 2015
Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper)
Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper)
Mount Sinai School of Medicine, New York
Allegheny General Hospital, Pittsburgh
Drexel University College of Medicine, Philadelphia
University of Pennsylvania, Philadelphia
University of Maryland, Baltimore
Medical University of South Carolina, Charleston
Cleveland Clinic Foundation, Cleveland
University of Wisconsin, Madison
Minneapolis Heart Institute, Minneapolis
University of Minnesota, Minneapolis
Northwestern University, Chicago
Medical City Dallas Hospital/CRSTI, Dallas
The Methodist Hospital, Houston
Intermountain Medical Center, Murray
Ronald Regan UCLA Medical Center, Los Angeles
Cedars Sinai Heart Institute, Beverly Hills
Stanford University/Palo Alto VA, Palo Alto
Stanford University, Stanford
University of California San Francisco, San Francisco
Tufts Medical Center, Boston
Massachusetts General Hospital, Boston
Brigham and Women's Hospital, Boston
Columbia University Medical Center, New York
University of Utah, Salt Lake City
Collaborators (1)
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Clinical Trials in Organ Transplantation
NETWORK
Genentech, Inc.
INDUSTRY
Rho Federal Systems Division, Inc.
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH